Outcomes & ratings

Who's on my team?

Based on specialized physician count, Mayo Clinic has one of the largest programs in the nation devoted to myeloma care. Our multiple myeloma program has over 40 physicians and researchers dedicated to treating myeloma.

Taxiarchis Kourelis, M.D., Hematology: Multiple myeloma is a blood cancer. It's the second most common blood cancer, but it's still a pretty rare cancer. It's 1 to 2% of all cancers, which comes down to about 35,000 new cases per year.

Wilson I. Gonsalves, M.D., Hematology: A lot of what we know about myeloma and where it originates that entire thought process was initiated out here at the Mayo Clinic.

S. Vincent Rajkumar, M.D., Hematology: Mayo Clinic has the largest multiple myeloma group anywhere in the world. Our group has developed what is called the M smart risk stratification and recommendations for myeloma therapy. The primary goal is to tell patients what is the current best treatment for myeloma, whether it be newly diagnosed for relapsed or maintenance.

We do a lot of cytogenetic testing on the bone marrow samples to find out precisely what type of myeloma patients have and what treatments they would respond to.

Rahma Warsame, M.D., Hematology: Everyone should get a second consultation and reviewed at a tertiary center when you have a disease like multiple myeloma, so then you're really making that fast decisions on the most novel therapies.

Taxiarchis Kourelis, M.D.Mayo has been at the forefront of clinical trial development and have really helped answer key questions about the optimal treatment approach of this disease. I think truly this is a watershed moment in the management of the disease. Immunotherapies that have affected other cancers, also coming into myeloma and revolutionizing the way we think about the disease and we treat the disease.

Wilson I. Gonsalves, M.D.: I always tell my patients there's a big army behind the scenes working for them. I have some of the world's best heart doctors, lung doctors, kidney doctors, surgeons ready to back me up in providing the best care for that patient. Hematopathologists, technicians and other researchers who in real time are working on either blood samples of clinical bone marrow samples to provide that information that I need to help provide the patients with options to make the best decision on treatment. Because physician treating a patient with multiple myeloma, you're not just treating that patient, your also helping their family or their loved one's understand more about the disease to help them take care of that patient.

Rahma Warsame, M.D.: Watching our colleagues work together for one patient, and it's a really multidisciplinary practice and leveraging the knowledge of decades and that history as well as all of the novel therapeutics to support our patients and continue to drive the science is going to make a difference.

Team-Based Care & Fast-Track Treatment

Based on specialized physician count, Mayo Clinic has one of the largest programs in the nation devoted to myeloma care. Our multiple myeloma program has over 40 physicians and researchers dedicated to treating myeloma.

Our multidisciplinary team-based care brings together experts who specialize in hematopathology, genetics, radiation oncology, orthopedic oncology, radiology and specialized imaging, interventional radiology, nephrology, bone, and neurology. These specialists are internationally recognized leaders in their field, and they work together to determine the best course and sequence of therapy according to your individual needs. This is embedded within an organization that focuses on multidisciplinary team-based care and is home to over 4,000 physicians and scientists.

In addition, our laboratory serves health care providers worldwide through genetic testing for patients at other institutions. Mayo Clinic does approximately 6,500 genetic tests for multiple myeloma each year for patients around the world. Mayo Clinic staff are recognized as experts by other laboratories and physicians.

Over 40 physicians and researchers dedicated to treating myeloma.

Mayo Clinic does approximately 6,500 genetic tests for multiple myeloma each year for patients around the world.

Outcomes & ratings

Expertise and experience

Specialized expertise combined with high patient volumes drive superior results at Mayo Clinic. In a typical year, Mayo Clinic providers see nearly 4,000 individual patients for multiple myeloma, and over 400 patients receive peripheral blood stem cell transplant for multiple myeloma at Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida. Each year, the Rochester campus of Mayo Clinic alone sees approximately 500 new patients for multiple myeloma care. Mayo Clinic also has broad expertise across the spectrum of disease related to myeloma, including monoclonal gammopathy, smoldering multiple myeloma, amyloidosis, POEMS syndrome and Castleman disease.

Patients seen annually for multiple myeloma at Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida

  • Nearly 4,000 patients seen for multiple myeloma
  • 400+ peripheral blood stem cell transplants for multiple myeloma
  • Approximately 500 new patients seen for multiple myeloma in Rochester, Minnesota

Minimal disruption to your life

We strive to provide world-class care with minimal disruption to your life. Mayo Clinic is a pioneer in performing outpatient peripheral blood stem cell transplant for multiple myeloma, a care model that can reduce cost and burden. Our autologous transplant program in Rochester, Minnesota, was established in 1989.

Outcomes from peripheral blood stem cell transplant for multiple myeloma at Mayo Clinic in Rochester, Minnesota

  • 0 days median inpatient hospital length of stay
  • 25% of patients age 75 or younger requiring inpatient hospital stay 5 days or more
  • 0.3% day-100 all-cause mortality
Source:
  1. Gertz MA, et al. Safety outcomes for autologous stem cell transplant in multiple myeloma. Mayo Clinic Proceedings. 2018; doi:10.1016/J.MAYOCP.2017.09.012.

Results that show in patient ratings

Patient satisfaction with Mayo Clinic is very high. Among patients with an outpatient office visit at Mayo Clinic for a diagnosis of multiple myeloma, 99% of survey respondents* gave Mayo Clinic the top or next-to-top rating when it came to reporting on overall satisfaction with care, likelihood of recommending Mayo Clinic and other key experience questions.

Good or very good (top two ratings) from respondents with an office visit for multiple myeloma†
Category Rating

*Surveys administered by Press Ganey

†Diagnosis of multiple myeloma accompanying 2019 office visit at Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida

Overall rating of care received during your visit 98.6%
Likelihood of recommending 98.6%
Our sensitivity to your needs 97.9%
Your confidence in this care provider 97.7%
Care provider's efforts to include you in decisions about your treatment 97.6%

World-class care

In a typical year, patients from over 20 countries and 50 U.S. states and territories receive care for multiple myeloma at Mayo Clinic.‡ Mayo Clinic is a leader in multiple myeloma research and analytics, with a focused research database established in the 1960s that continues today.

Patients with multiple myeloma had access to over 35 treatment clinical trials at Mayo Clinic in 2019, including studies across the spectrum of disease, from newly diagnosed multiple myeloma to relapsed and refractory disease. Because Mayo Clinic is a leader in research, patients at Mayo Clinic have access to therapies that are not available elsewhere.

Our myeloma care model is used all over the world with access to new evidence and guidelines via the Mayo Stratification for Myeloma & Risk-Adapted Therapy (mSMART) system, which reaches over 22,000 website visitors from the United States, Japan, China, India, Canada, Brazil and many other countries annually.

‡Office visit or peripheral blood stem cell transplant for multiple myeloma

Access to specialized physicians and scientists

Based on specialized physician count, Mayo Clinic has one of the largest programs in the nation devoted to myeloma care. Our multiple myeloma program has over 40 physicians and researchers dedicated to treating myeloma. Our multidisciplinary team-based care brings together experts who specialize in hematopathology, genetics, radiation oncology, orthopedic oncology, radiology and specialized imaging, interventional radiology, nephrology, bone and neurology. These specialists are internationally recognized leaders in their field, and they work together to determine the best course and sequence of therapy according to your individual needs. This is embedded within an organization that focuses on multidisciplinary team-based care and is home to over 4,000 physicians and scientists. In addition, our laboratory serves health care providers worldwide through genetic testing for patients at other institutions. Mayo Clinic does approximately 6,500 genetic tests for multiple myeloma each year for patients around the world. Mayo Clinic staff are recognized as experts by other laboratories and physicians.

Your care journey with Mayo Clinic doesn't stop when you return home

Mayo Clinic offers remote capability to monitor your case through eConsults with your local providers and telemedicine to your home. Mayo Clinic in Rochester, Minnesota, Phoenix and Scottsdale, Arizona, and Jacksonville, Florida, conducted over 34,000 virtual visits in January 2021 alone. Carry our expertise with you throughout your journey.

June 16, 2021
  1. Kaushansky K, et al., eds. Myeloma. In: Williams Hematology. 9th ed. McGraw Hill; 2016. https://accessmedicine.mhmedical.com. Accessed Sept. 1, 2020.
  2. Ferri FF. Multiple myeloma. In: Ferri's Clinical Advisor 2020. Elsevier; 2020. https://www.clinicalkey.com. Accessed Sept. 1, 2020.
  3. Niederhuber JE, et al., eds. Multiple myeloma and related disorders. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Sept. 1, 2020.
  4. Multiple myeloma. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Sept. 1, 2020.
  5. Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq. Accessed Sept. 1, 2020.
  6. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Sept. 1, 2020.
  7. Warner KJ. Allscripts EPSi. Mayo Clinic. June 24, 2020.
  8. Russell SJ, et al. Remission of disseminated cancer after system oncolytic virotherapy. Mayo Clinic Proceedings. 2014; doi:10.1016/j.mayocp.2014.04.003.
  9. Myeloma SPOREs. National Cancer Institute. https://trp.cancer.gov/spores/myeloma.htm. Accessed Sept. 4, 2020.
  10. AskMayoExpert. Multiple myeloma (adult). Mayo Clinic; 2019.
  11. Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology. 2016; doi:10.1016/S1470-2045(16)30206-6.
  12. Cavo M, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group. Lancet Oncology. 2017; doi:10.1016/S1470-2045(17)30189-4.
  13. Rajkumar SV, et al. Program genealogies: Myeloma at Mayo. The Hematologist. 2015; doi:10.1182/hem.V12.4.4166.
  14. Kyle RA, et al. Diagnostic criteria for the electrophoretic patterns of serum and urinary proteins in multiple myeloma. JAMA. 1960; doi:10.1001/jama.1960.03030030025005.